Delivery Order SPE2DB22D1106-SPE2DB25FDVG5

Award Date 1/21/25
Potential Completion Date 1/22/25
Potential Value $7.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug WEGOVY 1 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $1,259.78 and runs through November 28, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. The IDC serves as a primary...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,638.00, is for the delivery of the drug WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract is a firm fixed-price delivery order with a completion date of March 18, 2025. This award is not associated with a set-aside program. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug WEGOVY 1.7 MG/0.75 ML PEN 0.75ML. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 held by AmerisourceBergen with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract has an award value of $26,279.93 and is for the delivery of the pharmaceutical product WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract has an ultimate completion date of December 30, 2024 and is a Firm Fixed Price Delivery Order. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract is for the delivery of a pharmaceutical product, WEGOVY 1 MG/0.5 ML PEN 0.5ML, with a ceiling value of $3,229.59 and a completion date of January 6, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $8,435.89 and a period of performance through April 30, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as a primary vehicle...
This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,874.78, is a delivery order for the pharmaceutical product WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC enables...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,876.49, is for the delivery of the drug WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract is a Firm Fixed Price Delivery Order with a completion date of May 31, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This is a federal contract award by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $30,576.59, is for the delivery of the drug WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. This is a firm fixed-price delivery order contract with a completion date of January 9, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen also...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,735.57, is for the supply of the drug WEGOVY 1 MG/0.5 ML PEN 0.5ML. The award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as the primary vehicle...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB25FDVG5
    Delivery Order

This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the drug WEGOVY 1 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $7,302.12 and is a firm fixed-price delivery order that runs through January 22, 2025. AmerisourceBergen also holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition.

Generated 4/22/25, 9:44 AM